SLC5A2 and diabetic kidney disease: The Dutch Diabetic Nephropathy guideline recommends SGLT2 inhibitor therapy in two patient groups: (1) eGFR 30–60 mL/min per 1.73 m2 and UACR > 3 mg/mmol, and (2) eGFR ≥ 60 mL/min per 1.73 m2 and UACR > 30 mg/mmol [22].